Wockhardt Ltd News

Wockhardt soars 19% on huge volumes; here's why the pharma stock rose today

The company said the United States Food and Drug Administration (USFDA) has formally accepted the New Drug Application (NDA) for its first-in-class antibiotic 'Zaynich'

Ola Electric among top 10 stock losers in October; full list, strategy here

Ten out of Nifty 500 stocks declined up to 23% in October even as the Nifty and Nifty 500 gained around 4.5% each; should you buy these stocks or sell? Here's what the technical charts suggest.

BSE Smallcap index slips 2%; Symphony, Quess among 25 stocks at 52-week low

Thus far in the calendar year 2025, the BSE smallcap index has underperformed the market by falling 5%, as against 3% decline in midcap index and 3% rise in the BSE Sensex.

Shukra Pharma enters into pan-India distribution pact with Wockhardt

Shukra Pharmaceuticals on Wednesday said it has entered into a strategic non-exclusive Pan-India distribution arrangement with Wockhardt Ltd. The authorization is effective from September 9, 2025 and is valid until March 2026, an exchange filing said. The products include advanced anti-infective formulations and antibiotics developed to combat critical infections. The mandate includes distribution and management of products across all ESIC/ESIS hospitals and Defence/AFMSD/DGAFMS units throughout India, the filing said. "This collaboration further strengthens Shukra Pharmaceuticals presence in institutional and government healthcare networks across India, enhancing revenue visibility and operational footprint," the company said. Shukra Pharmaceuticals Limited is engaged in manufacturing and marketing pharmaceutical products as well as laboratory testing.

How Wockhardt's bet on multi-drug resistant infections is paying off

In India, Zaynich will be positioned as a third-line treatment, primarily for ICU patients when other antibiotics have failed

Wockhardt shares rise 2% after exiting US generics business

Wockhardt shares rose 2 per cent after it decided to exit the US generic pharmaceutical segment after incurring consistent losses

Wockhardt exits US generics biz, to focus on innovative portfolio

Wockhardt exits the US generics market after years of losses, shifting focus to new antibiotic drug discovery and biologicals, including insulin, to create long-term value.

Wockhardt exits US generics business, files for liquidation of subsidiaries

The decision follows years of financial losses in the US generics business, including loss of nearly $8 million in FY 2025, Wockhardt said in a BSE filing